Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients

被引:14
作者
Vonbank, Alexander [1 ,2 ,3 ]
Saely, Christoph H. [1 ,2 ,3 ]
Rein, Philipp [1 ,2 ,3 ]
Sturn, Daniel [2 ,3 ]
Drexel, Heinz [1 ,2 ,3 ]
机构
[1] VIVIT, Feldkirch, Austria
[2] Acad Teaching Hosp Feldkirch, Dept Med & Cardiol, Feldkirch, Austria
[3] Private Univ Principal Liechtenstein, Triesen, Liechtenstein
关键词
coronary artery disease; lipid goals; lipid management; high risk patients; hyperlipidemia; type; 2; diabetes; guidelines; 14; RANDOMIZED-TRIALS; LDL CHOLESTEROL; HIGH-RISK; METAANALYSIS; PREVENTION; EFFICACY; THERAPY; PARTICIPANTS; PEOPLE; SAFETY;
D O I
10.4414/smw.2013.13828
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Low density lipoprotein (LDL) cholesterol is a causative factor in coronary artery disease, and LDL cholesterol lowering by statins is a cornerstone in cardiovascular risk management. Current guidelines recommend serum LDL cholesterol <70 mg/dl for patients at very high risk, in particular for those with coronary arterial disease (CAD) or type 2 diabetes (T2DM). We aimed to investigate the proportion of patients achieving current lipid goals in two high-risk cohorts of CAD patients. MATERIAL AND METHODS: We obtained lipid profiles for two cohorts of patients who underwent coronary angiography for the evaluation of previously (>1 month) established CAD in 1999-2000 (n = 346) and in 2005-2007 (n = 850), at baseline and after 2 years of follow-up. RESULTS: Overall, the proportion of patients with baseline LDL cholesterol <70 mg/dl was 6.1% in the first and 7.3% in the second cohort (p = 0.236). In logistic regression analysis, male gender (odds ratio [OR] 1.33, 95% confidence interval [CI] 1.11-2.96; p = 0.021) and presence of diabetes (OR 1.76, 95% CI 1.30-2.38; p < 0.001) were independent predictors for reaching this LDL cholesterol treatment goal. After 2 years of follow-up, the proportion of patients with LDL cholesterol <70 mg/dl was 1.3% in the first and 9.5% in the second cohort (p < 0.001 for the comparison between the two cohorts; p = 0.001 for the comparison of cohort I at baseline vs after 2 years and p = 0.001 for the comparison of cohort II at baseline vs after 2 years). CONCLUSION: The proportion of CAD patients meeting current lipid treatment goals is low and has only slightly improved.
引用
收藏
页数:8
相关论文
共 23 条
[1]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[2]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]   Statins and stent thrombosis [J].
Braunersreuther, Vincent ;
Mach, Francois ;
Montecucco, Fabrizio .
SWISS MEDICAL WEEKLY, 2012, 142
[4]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[5]   Adherence to American diabetes association standards of care by rural health care providers [J].
Coon, P ;
Zulkowski, K .
DIABETES CARE, 2002, 25 (12) :2224-2229
[6]   PLASMA TRIGLYCERIDES AND 3 LIPOPROTEIN CHOLESTEROL FRACTIONS ARE INDEPENDENT PREDICTORS OF THE EXTENT OF CORONARY ATHEROSCLEROSIS [J].
DREXEL, H ;
AMANN, FW ;
BERAN, J ;
RENTSCH, K ;
CANDINAS, R ;
MUNTWYLER, J ;
LUETHY, A ;
GASSER, T ;
FOLLATH, F .
CIRCULATION, 1994, 90 (05) :2230-2235
[7]   RELATION OF THE LEVEL OF HIGH-DENSITY-LIPOPROTEIN SUBFRACTIONS TO THE PRESENCE AND EXTENT OF CORONARY-ARTERY DISEASE [J].
DREXEL, H ;
AMANN, FW ;
RENTSCH, K ;
NEUENSCHWANDER, C ;
LUETHY, A ;
KHAN, SI ;
FOLLATH, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (04) :436-440
[8]   European guidelines on cardiovascular disease prevention in clinical practice: executive summary [J].
Graham, Ian ;
Atar, Dan ;
Borch-Johnsen, Knut ;
Boysen, Gudrun ;
Burell, Gunilla ;
Cifkova, Renata ;
Dallongeville, Jean ;
De Backer, Guy ;
Ebrahim, Shah ;
Gjelsvik, Bjorn ;
Herrman-Lingen, Christoph ;
Hoes, Arno ;
Humphries, Steve ;
Knapton, Mike ;
Perk, Joep ;
Priori, Silvia G. ;
Pyorala, Kalevi ;
Reiner, Zeljko ;
Ruilope, Luis ;
Sans-Menendez, Susana ;
Reimer, Wilma Scholte op ;
Weissberg, Peter ;
Wood, David ;
Yarnell, John ;
Zamorano, Jose Luis .
EUROPEAN HEART JOURNAL, 2007, 28 (19) :2375-2414
[9]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421
[10]   Statins: have we found the Holy Grail? [J].
Jeger, Raban ;
Dieterle, Thomas .
SWISS MEDICAL WEEKLY, 2012, 142